COMMUNIQUÉS West-GlobeNewswire

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
06/06/2024
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund [...]
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
06/06/2024
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational [...]
PetVivo Appoints Former NOVUS and Colgate-Palmolive Senior Sales & Marketing Executive, Bryan Monninger, as VP of Sales
06/06/2024
MINNEAPOLIS, MN, US, June 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, has [...]
Castellum, Inc. Continues to Reduce Debt
06/06/2024
VIENNA, Va., June 06, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the "Company" or "Castellum") (NYSE-American: CTM) ($CTM), a cybersecurity, electronic warfare, and software services company focused on the federal [...]
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
06/06/2024
As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercise d to [...]
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
06/06/2024
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a [...]
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
06/06/2024
Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark, June 6, 2024 – Zealand [...]
European Bioplastics elects new Board with Mariagiovanna Vetere and Franz Kraus elected as Co-Chairs
06/06/2024
BRUSSELS, June 06, 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP), the association representing the interests of the bioplastics industry in Europe, has elected a new Board during its General Assembly on 4 June. [...]
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
06/06/2024
June 6, 2024 Company announcement No. 20 Incentive program for the Executive Leadership Team 2024-2026 In line with previous year, a new long-term incentive program (LTI) for the Executive Leadership Team covering the [...]
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
06/06/2024
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated [...]
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
06/06/2024
Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds will also enable [...]
Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum
06/06/2024
Press release Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum Qubit Pharmaceuticals joins the prestigious community of 100 disruptive technology startups. Over the [...]
Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
06/06/2024
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a [...]
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
06/06/2024
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 . Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN [...]
EUROAPI reaches major Health IPCEI milestone with official notification from European Commission
06/06/2024
Press Release Paris – June 6, 2024 – EUROAPI has received official notification from the European Commission that the Company has been selected as one of the 13 companies eligible to share up to EUR 1 billion in total [...]
EUROAPI franchit une étape majeure du PIIEC Santé avec la notification officielle de la Commission européenne
06/06/2024
Communiqué de presse Paris – Le 6 juin 2024 – EUROAPI a reçu la notification officielle de la Commission européenne selon laquelle l’entreprise fait partie des 13 sélectionnées pour se partager jusqu’à 1 milliard d’ [...]
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
06/06/2024
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 “alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a [...]
Annexon Announces Pricing of $125 Million Underwritten Public Offering
06/06/2024
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
06/06/2024
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and [...]

Pages